Regimen Reference Order – LEUK – azaCITIDine (AML)

ARIA: LEUK - [azaCITIDine (AML)]

Planned Course: Until disease progression or unacceptable toxicity (1 cycle = 28 days)

Indication for Use: Acute Myeloid Leukemia

CVAD: Not Required

Proceed with treatment if:

Cycles 1 to 4

 Proceed with treatment regardless of ANC and platelet value if the patient is feeling well (no signs or symptoms of infection)

Cycle 5 and Onwards

- ANC equal to or greater than 0.5 x $10^{9}/L$ AND Platelets equal to or greater than 50 x $10^{9}/L$
 - Consult Hematologist if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements			
Drug	Dose	CCMB Administration Guideline	
Not Applicable			

Treatment Regimen – LEUK – azaCITIDine (AML)			
Dose	CCMB Administration Guideline		
,			
8 mg	Orally 30 minutes before each dose of azaCITIDine		
75 mg/m²	Subcutaneous into abdomen * Alert: Maximum volume at each injection site is 4 mL *Nursing Alert: Air sandwich technique is recommended for administration		
	Dose 8 mg		

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Prior to each Cycle

• CBC, serum creatinine, urea, electrolytes and liver enzymes as per Physician Orders



Recommended Support Medications				
Drug	Dose	CCMB Administration Guideline		
None required				

DISCHARGE INSTRUCTIONS

- Instruct patient to report to clinic if they are experiencing injection site reactions that are bothersome
- Reinforce safe handling precautions of medications, blood and bodyfluids for 48 hours after completion of azaCITIDine

ADDITIONAL INFORMATION

- Due to limited room temperature stability, azaCITIDine MUST be stored in fridge until immediately prior to administration. DO NOT store at room temperature unless otherwise indicated by pharmacy
- All 7 doses of azaCITIDine must be administered within a 10-day period if not given consecutively

